Nothing Special   »   [go: up one dir, main page]

DE69412049D1 - Hemmung von dysfunctionalen Uterusblutungen - Google Patents

Hemmung von dysfunctionalen Uterusblutungen

Info

Publication number
DE69412049D1
DE69412049D1 DE69412049T DE69412049T DE69412049D1 DE 69412049 D1 DE69412049 D1 DE 69412049D1 DE 69412049 T DE69412049 T DE 69412049T DE 69412049 T DE69412049 T DE 69412049T DE 69412049 D1 DE69412049 D1 DE 69412049D1
Authority
DE
Germany
Prior art keywords
uterine bleeding
dysfunctional uterine
inhibition
chem
hexamethylenemino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69412049T
Other languages
English (en)
Other versions
DE69412049T2 (de
Inventor
Patrick Peter Keohane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69412049D1 publication Critical patent/DE69412049D1/de
Application granted granted Critical
Publication of DE69412049T2 publication Critical patent/DE69412049T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69412049T 1993-12-21 1994-12-19 Hemmung von dysfunctionalen Uterusblutungen Expired - Fee Related DE69412049T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,391 US5446053A (en) 1993-12-21 1993-12-21 Methods of inhibiting dysfunctional uterine bleeding

Publications (2)

Publication Number Publication Date
DE69412049D1 true DE69412049D1 (de) 1998-09-03
DE69412049T2 DE69412049T2 (de) 1999-01-14

Family

ID=22623570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69412049T Expired - Fee Related DE69412049T2 (de) 1993-12-21 1994-12-19 Hemmung von dysfunctionalen Uterusblutungen

Country Status (20)

Country Link
US (2) US5446053A (de)
EP (1) EP0659417B1 (de)
JP (1) JPH07215858A (de)
KR (1) KR950016726A (de)
CN (1) CN1109752A (de)
AT (1) ATE168887T1 (de)
AU (1) AU692490B2 (de)
CA (1) CA2138510A1 (de)
CZ (1) CZ321094A3 (de)
DE (1) DE69412049T2 (de)
DK (1) DK0659417T3 (de)
ES (1) ES2119094T3 (de)
GR (1) GR3027706T3 (de)
HU (1) HUT71469A (de)
IL (1) IL112037A (de)
NO (1) NO944930L (de)
NZ (1) NZ270167A (de)
PH (1) PH31099A (de)
RU (1) RU94044456A (de)
ZA (1) ZA9410080B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
WO1994026303A1 (en) 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CA2352461A1 (en) * 1998-11-26 2000-06-02 Tomohito Fujii Pharmaceutical composition for periodic administration
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
IN191020B (de) 2000-03-28 2003-09-13 Dabur Res Foundation
JP2004531559A (ja) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
US7056931B2 (en) * 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
KR102295878B1 (ko) 2021-06-16 2021-08-31 최경선 셀프용 등 지압기

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
HU9403663D0 (en) 1995-02-28
CN1109752A (zh) 1995-10-11
NZ270167A (en) 1997-08-22
EP0659417B1 (de) 1998-07-29
GR3027706T3 (en) 1998-11-30
IL112037A0 (en) 1995-03-15
DK0659417T3 (da) 1998-12-07
HUT71469A (en) 1995-11-28
PH31099A (en) 1998-02-05
ATE168887T1 (de) 1998-08-15
ES2119094T3 (es) 1998-10-01
CA2138510A1 (en) 1995-06-22
EP0659417A2 (de) 1995-06-28
US5552416A (en) 1996-09-03
IL112037A (en) 1999-03-12
AU692490B2 (en) 1998-06-11
EP0659417A3 (de) 1995-09-06
RU94044456A (ru) 1996-10-10
KR950016726A (ko) 1995-07-20
NO944930D0 (no) 1994-12-19
CZ321094A3 (en) 1995-08-16
JPH07215858A (ja) 1995-08-15
NO944930L (no) 1995-06-22
ZA9410080B (en) 1996-06-19
US5446053A (en) 1995-08-29
DE69412049T2 (de) 1999-01-14
AU8156194A (en) 1995-06-29

Similar Documents

Publication Publication Date Title
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
ATE150308T1 (de) Hemmung von thrombin
DE69412049D1 (de) Hemmung von dysfunctionalen Uterusblutungen
ES2172525T3 (es) Inhibicion de la fibrosis uterina.
DE69402165D1 (de) Hemmung von Seborrhoe und Akne
NO943873D0 (no) Hemming av bruskdegradering
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
DK0659414T3 (da) Inhibering af hirutisme og alopeci hos kvinder
FI970716A (fi) Menetelmiä primaarisen kohdun limakalvon liikakasvun estämiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee